The decision to pause its investment in Britain came as AstraZeneca announced plans to spend $3.5bn (£2.7bn) expanding its US ...

Reading ‘Australia’s Pandemic Exceptionalism’ and this official response report is essential for anyone likely to have ...

This column, forecasting a Trump election win, last week expressed surprise so many news consumers remain loyal to media ...

The 868-page report of the official inquiry into Australia’s Covid-19 response, like the inquiry itself, is not fit for ...

Controversy followed close on the heels of a recent study on the long-term safety of Covaxin, the Covid-19 vaccine developed by Bharat Biotech in collaboration ...

AstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, but AstraZeneca stock slipped amid a criminal probe in China.

Chiropractors for RFK —Three appeals in a pod —The FDA shortage saga —The ghost of elections past And more! Join the conversation here.

A long negative candle was formed on the daily chart after the upside bounce of the last two sessions. The crucial overhead ...

Influenza and 2023 to 2024 COVID-19 vaccination coverage is 80.7 and 15.3%, respectively, among health care personnel at ...

COVID-19 vaccination coverage has progressed unevenly throughout the world. Moreover, 1.01 and 1.43 doses for each person are ...